Astrazeneca (AZN) Income from Non-Controlling Interests (2009 - 2026)

Astrazeneca has reported Income from Non-Controlling Interests for 18 years, with the latest figure at $1.0 million in Q2 2026.

• On a quarterly basis, Income from Non-Controlling Interests rose 150.0% year-over-year to $1.0 million in Q2 2026; TTM through Jun 2026 was -$821.0 million, a 13783.33% decrease from a year earlier, with the FY2025 full-year figure at $8.0 million, up 33.33% from the prior year.
• Income from Non-Controlling Interests was $1.0 million for Q2 2026 at Astrazeneca, roughly flat from $1.0 million in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $5.0 million in Q1 2025, with the low at -$825.0 million in Q4 2025.
• Average Income from Non-Controlling Interests over 5 years is -$47.2 million, with a median of $1.0 million recorded in 2022.
• The largest YoY upside for Income from Non-Controlling Interests was 400.0% in 2025 against a maximum downside of 82400.0% in 2025.
• Over 5 years, Income from Non-Controlling Interests stood at $1.0 million in 2022, then slumped by 200.0% to -$1.0 million in 2023, then changed by 0.0% to -$1.0 million in 2024, then tumbled by 82400.0% to -$825.0 million in 2025, then jumped by 100.12% to $1.0 million in 2026.
• The last three Income from Non-Controlling Interests figures came in at $1.0 million (Q2 2026), $1.0 million (Q1 2026), and -$825.0 million (Q4 2025), per Business Quant data.